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doi:10.1016/j.ejvs.2010.12.006Abstract Introduction: The optimal treatment of asymptomatic carotid disease is being
debated again. The conclusions of the large randomised controlled trials of the early 1980s
and 1990s are increasingly being questioned due to advances in modern medical treatment.
This study investigates how patients are actually managed medically related to general risk
factors prior to carotid endarterectomy in a German health-care region.
Materials/Methods: A prospective data bank including 95 consecutive patients was used. The
effectiveness of lipid lowering and diabetes management were investigated as well as the use
of anti-thrombotic and blood pressure medication.
Results: A total of 108 carotid endarterectomies in 95 patients were performed between
January 2009 and March 2010. All 95 patients (70 male, 25 female; 39 symptomatic/56 asymp-
tomatic) were included in the study. Nearly half (54%) of the patients were on statins; of these,
45% had low-density lipoprotein (LDL) levels >100 mg dl1. Of 32 patients with diabetes, one
had glycohaemoglobin (HbA1c) <6.0. Overall, four patients were on clopidogrel. Three patients
were severely hypertensive (systolic blood pressure >180 mmHg).
Conclusions: The best medical therapy for carotid disease is not optimal in the part of the
German health-care system observed in this study. We strongly advocate similar audits in other
health-care areas and systems.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Carotid endarterectomy (CEA) was shown to provide an
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502 H.J. Lutz et al.conducted up to three decades ago (1983e2003). The latest
results6 of the Asymptomatic Carotid Surgery Trial (ACST)4
study demonstrated a stroke reduction of 18% versus 13%
at 10 years in asymptomatic patients in favour of CEA.
However, the absolute risk reduction is small, approxi-
mately 1% per year over the first few years of follow-up.
New drugs as well as better understanding of lifestyle-
related factors are thought to offer a new dimension in the
management of asymptomatic carotid stenosis.7,8 Lifestyle
modification includes cessation of smoking, weight control
(diet) and physical activity.9 Used in secondary prevention,
the new drugs have been shown to reduce all-cause
mortality and offer clear benefits across broad pop-
ulations.10 It is now estimated that medical intervention
alone is 4e8 times more cost effective7 than surgery or
stenting. In that setting, the key is what ‘best medical
therapy’ really means and how well it is used. Best medical
therapy includes lipid-lowering therapy (LLT), control of
hypertension, anti-platelet therapy and control of diabetes
(European Stroke Initiative 2003).11 This audit investigates
how patients are actually managed medically prior to CEA
in a highly developed health-care system in a specified area
in Germany. Are the much publicised new agents actually
used as suggested by international guidelines?Table 1 Patients characteristics.
Characteristics Number/
Mean
Percent/
SD
Male 70 73.7%
Age 73.61  8.6
Symptomatic TIA/PRIND/
Stroke
39 41.1%
Contralateral
stenosis
No 54 56.8%
50%e70% 19 20.0%
>70% 13 13.7%
Occlusion 9 9.5%
COPD 15 15.8%
Diabetes 32 33.7%
Hypertension 85 89.5%
b Blockers 57 60.0%
ACE Inhibitors 58 61.1%
Calcium
Antagonists
40 42.1%
Diuretics 41 43.2%
AT1-Antagonists 26 27.4%
Anticoagulation ASS 66 69.5%
Clopidogrel 4 4.2%
Warfarin 14 14.7%
Dipyridamol/
Aspirin
3 3.2%
HepPerfusor25000 I.U. 7 7.4%
CAD 39 41.1%
Renal failure 4 4.2%
PAOD 28 29.5%
Lipid-lowering therapy 51 53.7%
Smoking 24 25.3%Material and Methods
Hospital records of 95 consecutive patients hospitalised for
108 elective CEAs were collected from 1 January 2009 to 30
March 2010 and placed in a prospective data bank. St.
Marien Hospital in Hamm is situated in a densely populated
health-care region (200,000 inhabitants and three hospitals
with 1200 beds) in the western part of Germany. There are
300 general practitioners in the region. Of these, the
number of trained cardiologists, specialists of internal
medicine, angiologists and vascular surgeons is as high as
the society of physicians allows. In Germany, the maximum
number of physicians in an area is limited by the number of
inhabitants. Highly competent health care should theoret-
ically be available to all.
Primary outcome was the effectiveness of LLT and
management of diabetes, as well as prescribed anti-throm-
botic and blood pressure medications. Secondary outcome
was related to surgery: stroke and death. No comp-
arisons between medical management and surgery were
attempted.
Indication for surgery was asymptomatic carotid stenosis
>80% and symptomatic stenosis >70%. Surgery was per-
formed using local or general anaesthesia. CEA was per-
formed conventionally, using patch closure in all cases. All
patients were seen by a neurologist pre- and post-opera-
tively within 30 days of surgery.
For the analysis, risk factors and medical treatment were
recorded. The effectiveness of LLT was monitored by quan-
tifying cholesterol, low- and high-density lipoprotein (LDL
and HDL) as well as triglycerides. The quality of diabetes
management was assessed by recording glycohaemoglobin
(HbA1c). Height and weight were measured to evaluate the
body mass index (BMI). The number and classification of
agents controlling hypertension as well as episodes of
hypertension during hospital stay were stated. Patients wereinterviewed for lifestyle modifications with respect to ciga-
rette smoking and diet advice.
Statistics
For comparison of groups, we used the chi-square test for
categorical variables and a non-parametric (ManneWhitney
test) for metric variables. A p-value below 0.05 was
considered significant. All analyses have been performed
using Statistical Package for Social Sciences (SPSS) 17.0.
Results
A total of 108 CEAs in 95 patients were performed during
the study period. Of these, 13 had a staged bilateral
operation. All the patients were included in the study (see
Table 1 for patients’ characteristics). Thirty-nine patients
(41%) had symptomatic carotid stenosis. Twenty-five (26%)
presented after a stroke and 14 (15%) after a transient
ischaemic attack. Symptomatic stenosis was indication for
surgery in 15 (60%) women and 24 (34%) men (p Z 0.03).
In the area of lifestyle and risk management, 24 (25%) of
the 95 patients were still smoking. No patient, including the
ones on statins, had ever had diet advice. BMI was
<25 kg m2 in 23 (24%), between 25 and 30 kg m2 in 58
(60%) and >30 kg m2 in 14 (15%) cases.
Figure 2 Histogram of cholesterol levels.
Wishful Thinking in Carotid Disease 503Thirty-two patients (34%) suffered from diabetes. Of
these, 31 (97%) had HbA1c > 6.0.
Sixty-six (70%) patients were on aspirin, 14 (15%) on
warfarin, four (4%) on clopidogrel, three (3%) on dipyr-
idamole/aspirin and seven (7%) on heparin. One patient
(1%) had no anti-thrombotic therapy. Twenty-three (59%) of
the 39 symptomatic patients had aspirin, three (8%) clopi-
dogrel, four (10%) warfarin, two (5%) dipyridamole/aspirin
and seven (18%) heparin. The same numbers for asymp-
tomatic patients, respectively, were 43/56 (77%), one (2%),
10 (18%), one (2%) and none (0/56). All the patients with
heparin had a history of stroke.
A total of 85 (90%) patients were treated for hyperten-
sion. b-blockers were administered in 57 (60%) patients,
angiotensin-converting enzyme (ACE) inhibitors in 58 (61%),
calcium antagonists in 40 (42%), diuretics in 41 (43%) and
AT1-antagonists in 26 (27%). Three patients (3%) were
severely hypertensive (RR >180 mmHg) during hospital stay
and needed adjunct therapy. There was no significant
difference in administered drugs for blood pressure control
between asymptomatic and symptomatic patients.
As many as 65 (64%) of the patients had elevated LDL
levels (>100 mg dl1) (Fig. 1), 38 (40%) elevated cholesterol
levels (Fig. 2) and 24 (25%) elevated triglyceride levels
(Fig. 3). Of the 51 (54%) patients on statins, 23% (45%) had
elevated LDL levels. The patients on statins had signifi-
cantly lower mean LDL and cholesterol levels (p Z 0.0001
for both parameters) (Table 2). There were no significant
differences in prescribed statins and elevated LDL as well
as cholesterol levels between symptomatic and asymp-
tomatic patients (Fig. 4).
After surgery, there was one (1.1%) death due to
myocardial infarction operated on for symptomatic
stenosis. No transient attack or stroke was observed. The
combined stroke and death rate was 1.1%.
Discussion
According to the World Health Organization’s statistics,
atherosclerotic disease is, worldwide, by far the mostFigure 1 Histogram of LDL levels.important cause of death. Genetic risk factors are impor-
tant, but, at the time, some 300 other risk factors are
known in coronary arterial disease alone.12 Well-known risk
factors include smoking, obesity, hyperlipidaemia, diabetes
and hypertension. The knowledge and understanding of the
key risk factors offer the clinician a window of opportunity
in the prevention of various complications of the disease,
such as those caused by carotid stenosis. Arterial disease is
a spectrum of pathology and symptoms. Therefore, primary
and secondary prevention are not always clear-cut entities.
A patient may have symptoms from one territory but not
from another.
Currently, there is no clear consensus regarding the best
treatment of asymptomatic carotid disease. Surgery has
traditionally been supported as the treatment of choice by
the guidelines of the American Heart Association e mainly
based on randomised controlled trials (RCTs) completed up
to three decades ago. Successful CEA for asymptomatic
disease is now known to reduce the risk at 10 years in
patients younger than 75 years of age, half of the reductionFigure 3 Histogram of triglycerid levels.
Table 2 Effect of lipid-lowering therapy.
LLT treated LLT untreated p-value
Mean  SD Min Max Mean  SD Min Max
chol 172.25  40.88 103 267 219.39  45.31 146 313 0.000
ldl 103.18  34.37 37 212 139.11  36.91 69 235 0.000
hdl 43.51  14.73 20 95 49.16  17.22 23 98 0.124
504 H.J. Lutz et al.being in disabling or fatal strokes. However, the absolute
risk reduction is very small, approximately 1% per year over
the first few years of follow-up, and the overall gain is low,
less than 5%.6
Recently, medical management alone has been shown to
be effective in reduction of stroke among patients with non-
subcategorised50e99% carotid stenosis in a systematic review
by Abbott.7 These results provide that patients are medically
managed according to the available recommendations. The
aim of our audit was to investigate whether patients with
carotid stenosis are managed according to these.
‘Best medical therapy’ as a term tends to be overused at
times. The recommendations for carotid disease have been
defined in the European Stroke Initiative and include control
of hypertension, diabetes, statin therapy, smoking cessa-
tion, avoiding heavy consumption of alcohol, regular physical
activity, nutrition, weight reduction, aspirin, dipyridamol
and clopidogrel.11,13
Newer drugs reduce the risk of stroke the same way
myocardial infarction can be prevented in many cases.
Statins (Coenzyme A reductase inhibitors) were not avail-
able at the time when the RCTs were conducted (with the
partial exception of the ACST Trial). The clearly beneficial
effect of LLT to prevent stroke has been seen in many trials
and presented in a large meta-analysis in 2004.14 In our
study, 54% of our patients had been prescribed statins. Of
these, 48% had previously diagnosed coronary artery
disease and 24% peripheral arterial occlusive disease.
Nearly half (45%) of the patients had elevated LDL levels,
despite active therapy. We observed that cholesterol and
LDL levels were significantly lower among the patients who
were actually taking statins.Figure 4 Histogram of HbA1c levels.Anti-platelet treatment with aspirin was common and wi-
dely used15 during the RCTs. There is evidence suggesting that
newer agents such as clopidogrel16 or dual anti-platelet ther-
apywithaspirin andclopidogrel17 or aspirin anddipyridamole18
aremore effective in preventing vascular complications. In our
patients, anticoagulant and anti-platelet therapy seemed to
meet the standard, but aspirin, warfarin and heparin have
been available from the beginning of the carotid RCTs. Clopi-
dogrel or combined dipyridamole and aspirin were adminis-
tered in only 7% of our patients.
The importance of controlling hypertension was also
known during the RCTs. The effects of b-blockers and ACE
inhibitors were known in blood pressure control as well as in
the prevention of ischaemic events.19 ACE inhibitors, unlike
b-blockers, are now known to have a pleiotropic effect on
the endothelium.20 Hypertension seemed to be the most
efficiently treated disease in our audit.
What are generally the reasons for the clearly less
than optimal medical therapy?
The cost can be a factor as well as lack of compliance among
patients21 e or physicians.22 The overall cost of LLT is high in
any society. Newer anti-platelet drugs, such as clopidogrel,
are relatively expensive as well, although generic prepara-
tions have recently been made available. Abbott, in her
overview, estimated medical management to be 4e8 times
more cost effective than CEA, while Henriksson et al.23 sug-
gested that CEA, in addition to best medical therapy, may be
considered cost effective inmen less than 73 years. However,
even after 15 years of follow-up, CEAwasnot shown tobe cost
effective in asymptomatic females.
Patient compliance with regard to lifestyle changes is
a major issue. In our study, 75% of the patients were over-
weight, 25% were still smoking and their diabetes was poorly
controlled. All but one diabetic patient (31 of 32) were found
to have elevated HbA1c. As such, a study by Duckworth et al.
showed that very strict glucose control may not have
a significant effect on the rates of major cardiovascular
events.24 By contrast, a large randomised study by the Action
in Diabetes and Vascular Disease: Preterax and Diamicron
Modified Release Controlled Evaluation (ADVANCE) Collabo-
rative Group among 11 000 patients did show a 10% relative
reduction in the combined outcome of major macro- and
micro-vascular events, primarily as a consequence of a 21%
relative reduction in nephropathy.25 Factors related to life-
style modification are discussed very actively today. The
vicious circle of overweight, diabetes and vascular compli-
cations, such as myocardial infarction, stroke, renal
dysfunction and the risk of amputation, particularly among
smokers, has never been presented as clearly.26 Information
and help are offered by media and various public health
Wishful Thinking in Carotid Disease 505organisations. Still, in most Western countries, obesity has
become more common e and with it, diabetes and
the vascular problems related to it.27,28 For any prevention
strategy to work, it should be adhered to. The expectations
regarding prevention of adverse effects of the disease are
clear on both sides e the patients and the clinicians e but
they are not always met. There is a clear underutilisation of
resources.
How well can the results of our audit be
generalised?
Lack of compliance to any medical treatment e be it opera-
tive or conservative e is a common problem all over the
world. Systematic data shows that, in the US, non-adherence
of patients undergoing dialysis is 8.5e86% with regard to
different aspects of therapy.29 Non-compliance is common
even in management of malignant disease, where it has been
shown to increase morbidity and mortality.30 Similar findings
have been shown in France and Italy. A French study31 shows
that non-adherence to medications was 32% for b-blockers,
24% for statins, 23% for ACE inhibitors as well as angiotensin-
receptor blockers and 18% for clopidogrel among patients
after myocardial infarction. Non-adherence to evidence-
based therapywas 50% overall. Tarantino et al.32 showed that
42% of uniformed patients were non-adherent to therapy,
and, even among well-informed patients, non-compliance
was seen in 21% of the patients.
A study by Ceral et al.33 in the Czech Republic analysed
the serum levels of medications using chromatography
among patients with seemingly drug-resistant hypertension
receiving at least three drugs. In 35% of the patients, none
of the prescribed drugs was present in the serum. Non-
adherence was seen in 65% of the patients. The reasons for
non-compliance were not analysed, but it may be common
as hypertension rarely presents with symptoms e nor does
asymptomatic carotid stenosis, by definition.
In summary, adherence to the recommendations in our
audit was poor.
What does the future bring?
Primary prevention strategies should still be improved,
especially as, for instance, aspirin has essentially no value in
it.34 Perhaps, kindergartens and schools are the places for
such programmes. Maybemobile phone-based reminders and
other similar strategies based on modern communication
technologies could work for adults. An overview of the types
of strategies needed to prevent obesity using a comprehen-
sive population-based approach rather than relying only on
physician-based or individually oriented strategies was
recently published by Kumanyika et al.35 Modern studies such
as the meta-analysis by Abbott may have rendered further
randomised CEA studies obsolete in the future, but ongoing
ones such as the German three-armed Space-2 trial36
comparing endarterectomy, stenting and best medical
treatment may give us more answers concerning medical
therapy and its role in preventing stroke among patients with
carotid stenosis. Furthermore, promising new and more
effective drugs such as direct thrombin inhibitors, keep
appearing. Medical intervention would be even cheaper perevent prevented, if other complications such myocardial
infarction or leg ischaemia were also considered e and it
makes CEA safer and is crucial for symptomatic patients
waiting for an operation as well.
Limitations of the study
This study is based on a very small sample in one health-
care region of Germany. It is not powered to answer the
question of how to treat severe asymptomatic carotid
stenosis at all. We still hope to contribute to the recent
lively transatlantic debate.37,38 The data were collected
prospectively and accurately. Reasons for non-adherence to
therapy or lifestyle modifications should be analysed in
larger populations. It is unclear to which extent the results
of the audit can be generalised. Future audits should
include exact information on which class of the expected
medications the patients were on, especially anti-platelet
agents, anti-hypertensives, antidiabetics and lipid-lowering
medications, and reasons for omission of these drugs.
Conclusions
For the time being, best medical therapy for carotid
disease is not optimal in the part of the German health-care
system observed in this study. We strongly advocate similar
audits in other health-care areas and systems.
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